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Abstract
Introduction: Proper standardization of laboratory testing requires assessment of performance after the tests are performed, known as the post-
analytical phase. A nationwide external quality assessment (EQA) scheme implemented in Croatia in 2014 includes a questionnaire on post-analyti-
cal practices, and the present study examined laboratory responses in order to identify current post-analytical phase practices and identify areas for 
improvement. 
Materials and methods: In four EQA exercises between September 2014 and December 2015, 145-174 medical laboratories across Croatia were 
surveyed using the Module 11 questionnaire on the post-analytical phase of testing. Based on their responses, the laboratories were evaluated on 
four quality indicators: turnaround time (TAT), critical values, interpretative comments and procedures in the event of abnormal results. Results 
were presented as absolute numbers and percentages.  
Results: Just over half of laboratories (56.3%) monitored TAT. Laboratories varied substantially in how they dealt with critical values. Most laborato-
ries (65-97%) issued interpretative comments with test results. One third of medical laboratories (30.6-33.3%) issued abnormal test results without 
confirming them in additional testing. 
Conclusion: Our results suggest that the nationwide post-analytical EQA scheme launched in 2014 in Croatia has yet to be implemented to the full. 
To close the gaps between existing recommendations and laboratory practice, laboratory professionals should focus on ensuring that TAT is moni-
tored and lists of critical values are established within laboratories. Professional bodies/institutions should focus on clarify and harmonized rules to 
standardized practices and applied for adding interpretative comments to laboratory test results and for dealing with abnormal test results. 
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Introduction
Comparability of laboratory test results depends 
on standardization of all phases of laboratory test-
ing, including pre-analytical, analytical and post-
analytical phases. Pre-analytical and analytical 
phases of laboratory testing aim to generate an 
accurate test result, while the post-analytical 
phase - when the clinician receives the test results, 
interprets them, and uses them to make diagnos-
tic and therapeutic decisions - aims to reduce er-
rors or bias associated with the hand-off from lab-
oratory to clinician. The most frequent errors in 
the post-analytical phase are erroneous validation 
of analytical data, failure to report test results to 
appropriate parties, excessively long turnaround 
time (TAT), mistakes in data entry, manual tran-
scription errors and failure or delay in reporting 
critical values (1). 
Despite the obvious importance of the post-ana-
lytical phase to overall laboratory performance, 
many providers of external quality assessment 
(EQA) schemes do not take into account the post-
analytical phase (2). In 2009, the Croatian Chamber 
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of Medical Biochemists (CCMB) and Croatian Soci-
ety of Medical Biochemistry and Laboratory Medi-
cine (CSMBLM) assessed the state of pre- and post-
analytical procedures in medical laboratories 
across the country (3). The results indicated ur-
gent, substantial need for improvement. There-
fore, a nationwide EQA scheme covering the post-
analytical phase was implemented in 2014, admin-
istered by the Croatian Centre for Quality Assess-
ment in Laboratory Medicine (CROQALM) within 
the CSMBLM. The EQA scheme is implemented 
modularly three times per year. The CCMB made 
participation in the scheme mandatory for all 
medical laboratories in Croatia in 2013 (4). In the 
second EQA exercise of 2014, pilot modules on 
pre- and post-analytical phases were introduced; 
in all three EQA exercises of 2015, Module 11 deal-
ing with the post-analytical phase was performed. 
The present study was undertaken to evaluate to 
what extent the recently introduced nationwide 
EQA scheme for the post-analytical phase of labo-
ratory testing has influenced laboratory practice in 
Croatia. Since laboratories showed substantial var-
iation in post-analytical practices before the 
scheme (3), we felt it necessary to evaluate the 
success of the EQA scheme at this early stage in or-
der to identify the more important issues and im-
plementation gaps and thereby help regulators 
and laboratory directors focus their energies more 
efficiently in the coming years. In a separate publi-
cation, we will assess pre-analytical procedures us-
ing an EQA module for the pre-analytical phase 
developed by the CSMBLM.
Module 11 is an educational module about the 
post-analytical phase of laboratory testing, and it 
contains an optional questionnaire that presents 
medical laboratories with routine post-analytical 
scenarios where standardized practices exist un-
der the Croatian EQA scheme or where clear rules 
are lacking (‘grey areas’). The present study retro-
spectively analysed laboratory responses to this 
questionnaire in 2014-2015 in order to (a) gain on-
the-ground insights into current laboratory prac-
tices in Croatia and (b) identify the most urgent ar-
eas for improving the standardization of the post-
analytical phase in Croatian laboratories. 
Materials and methods
Study design
This retrospective, longitudinal study involved 
analysis of the responses of Croatian medical labo-
ratories to a questionnaire distributed during four 
national EQA exercises conducted in September 
2014 and in May, September and November 2015. 
During this study period, 194 medical laboratories 
were registered in the Croatian health care system, 
comprising 125 (64%) medical laboratories from pri-
mary health care facilities (including private medi-
cal practices and private laboratories) and 69 (36%) 
medical laboratories from secondary and tertiary 
health care centres (clinical hospital centres, clini-
cal hospitals, general hospitals, national hospitals, 
and special hospitals). Although all medical labora-
tories were obliged to participate in the national 
EQA scheme, their responses on the questionnaire 
were voluntary. Laboratories were told that their re-
sponses would not affect their overall assessment 
from CROQALM. No fees or compensation were in-
volved in completing the questionnaire.
Data from all responding laboratories were used in 
the present study; no exclusion criteria were ap-
plied. When they filled out the questionnaire, lab-
oratories gave consent for the data to be stored 
and used by CROQALM for group-level analyses. 
Members of CROQALM signed statements that they 
would safeguard the confidentiality of EQA data.   
Questionnaire
Questionnaires have been proposed as an effec-
tive method for assessing the post-analytical 
phase during EQA exercises (2). The Croatian EQA 
questionnaire was designed by CROQALM, ap-
proved by CSMBLM and CCMB, and distributed to 
all registered medical laboratories in the country. 
The responses were analysed by the EQA provider 
(CROQALM), and one of the authors (JLK) annotat-
ed the results in her capacity as EQA/CROQALM 
Module 11 coordinator. All these steps, from de-
sign to final analysis, were conducted via Web in-
terface using inlab2*QALM software, specifically 
designed in 2011 for quality evaluation of medical 
laboratory performances (IN2 Group Ltd., Zagreb, 
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Croatia). Medical laboratories receiving the ques-
tionnaire were instructed to ask their laboratory 
manager or laboratory professionals (or quality 
control manager) to fill it out.
The questionnaire was part of Module 11, entitled 
‘Post-analytical phase of laboratory testing’, which 
explained post-analytical practices under the new 
Croatian EQA scheme. It consisted of closed-type 
questions covering four indicators of post-analyti-
cal quality proposed by the Working Group ‘Labo-
ratory Errors and Patient Safety’ of the Internation-
al Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) (5). The questions described spe-
cific situations or scenarios often encountered in 
routine practice concerning TAT, critical values, in-
terpretative comments and procedures (repetition 
or additional testing) in the event of abnormal test 
results. Participants could choose only one of the 
offered responses for each question. Responses to 
12 questions administered during one or more of 
the four exercises during the study period were 
analysed. 
Data analysis
Data were not analysed statistically. Instead, re-
sults were reported as absolute numbers and per-
centages.  
Results
The number of medical laboratories participating 
in each exercise varied, as did the number that 
filled out the questionnaire; Figure 1 presents a 
histogram of response rates to questions. The re-
sponse rate was always more than 80% of labora-
tories participating in the exercise. Table 1 pre-
sents the contents of the questionnaire, which var-
ied with the exercise. 
Responses to the questionnaire were analysed to 
determine to what extent medical laboratories 
comply with existing rules issued by professional 
bodies in Croatia, and to identify how medical lab-
oratories are likely to proceed in frequent yet ‘grey’ 
situations where no clear rules exist. Frequencies 
of different responses to all questions are shown in 
Table 1 where answers that are clearly non-com-
pliant with existing rules are emphasised in ques-
tion comment. While laboratory respondents 
showed good knowledge of the definition of TAT, 
only approximately half of respondents reported 
that they routinely monitor TAT. Most respondents 
(85.7%) showed good knowledge of the definition 
of critical values (reflected in five questions) and of 
recommendations on how to apply the definition. 
On the other hand, the laboratories showed sub-
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Table 1. Questions and possible responses on the Module 11 questionnaire, by EQA exercise, together with the number (%) of re-
spondent laboratories choosing that response. 
Year and EQA 









1. The patient (male, 65 years) has a diagnosis of increased heart pressure and 
cardiac fibrillation and has been on antihypertensive and oral anticoagulant 
therapy for several months. He comes to the clinic for monthly check of 
prothrombin time (PT, INR). The patient is in generally good condition and has 
not altered warfarin dose or antihypertensive therapy in the last month. Target 
INR for his diagnosis is 2.5 (range 2.0 – 3.0). The measured value of INR is 1.9. In 
the history of the laboratory test results for this patient, INR values range from 
2.3 to 2.8.
His blood sample is regular, without any written comments from the 
pre-analytical phase. The sample was collected properly to the mark, without 
visible clots, haemolysis or lipemia and there were no notes about patient 
characteristics. The internal control on that day for PT was the target value of the 
control sample used.
In this situation, you would:
a) confirm and issue the laboratory test results without any comments. 22 (14.3)
b) confirm and issue the laboratory test results without any comments, after 
repeating the test and obtaining the same value again.
81 (52.6)
c) contact the patient to find out what might have altered the value of PT, INR 
and, with the patient’s consent, repeat the blood sampling and measurement 
before issuing laboratory test results.
6 (3.9)
d) inform the patient’s physician about the PV, INR results and, in consultation 
with him or her, decide on whether to repeat the blood sampling.
33 (21.4)
e) confirm the test results and issue them with a comment, such as ‘Repeat 








2. A male infant with congenital malformation of the abdominal wall (diagnosis: 
gastroschisis) is admitted to the intensive care unit. Urgent measurements 
are made of blood gases, acid-base balance, electrolytes and glucose from a 
capillary blood sample. The concentration of blood glucose is 2.1 mmol/L, and 
the results for pH, blood gases and ionized electrolytes are within the reference 
ranges for his age. In this situation, you would:
a) telephone the physician immediately after the analysis, inform him or her 
about glucose concentration (recommended critical value for glucose is < 2.5 
mmol/L according CCMB), and record in the appropriate log that the clinician 
was notified.
51 (35.2)
b) confirm and release the results immediately after analysis (with no phone 
contact with the physician), since all measured values are within the reference 
range for the patient’s age.
94 (64.8)
c) urgently request repeat of blood sampling to confirm the laboratory test 
results.
0 (0.0)





3. The time required for the issue of laboratory test results (turnaround time, TAT) 
in your laboratory is:
a) clearly defined and monitored for all analyses in the laboratory. 30 (19,0)
b) defined and monitored only for emergency analysis of first and second 
category.
59 (37.3)
c) not monitored, but the laboratory test report displays the time of sample 
receipt and the time of issue of results.
44 (27.9)
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d) not defined or not monitored at all, with all analyses performed as soon as 
possible.
15 (9.5)
e) defined, but not monitored. 10 (6.3)
Comment: Non-compliant answers: d) and e) .
2015,
first exercise TAT
1. The starting point for measuring TAT is:
a) when a physician’s request for laboratory tests is received at the laboratory. 5 (2.9)
b) when the sample is taken. 30 (17.2)
c) when the sample is received at the laboratory. 91 (52.3)
d) when the sample enters preparation for analysis. 1 (0.6)
e) when the sample enters into the analytical procedure. 0 (0.0)
f) variable and should be defined by each laboratory depending on the type of 
laboratory and tests performed there (emergency, routine, primary health care 
or hospital laboratory). 
47 (27.0)





2. Extremely high values are obtained for parameter X using an immunochemical 
assay. These values are confirmed in repeated measurements and in dilution, 
yet they are inconsistent with the patient’s clinical presentation. Internal quality 
control values for parameter X are within the acceptable limit. In this situation 
you would:
a) repeat the blood sampling after consulting a physician. 43 (24.7)
b) verify the laboratory test result without consulting a physician because you 
have already done everything possible to verify the high values.
5 (2.9)
c) verify the high values after consulting a physician. 47 (27.0)
d) measure parameter X using another method (your own or that of another 
laboratory) before verifying the laboratory test result or consulting a physician.
51 (29.3)
e) consult a physician and verify the laboratory test result, then measure 
parameter X using another method (your own or that of another laboratory).
28 (16.1)
f) Call technical support. 0 (0.0)






1. Measured and re-measured blood glucose from the same blood sample from 
an outpatient is 11.4 mmol/L. During venepuncture, the patient states that he 
has been fasting and is not taking any medications. In this situation, you would:
a) proceed as if the test result were a critical value and promptly notify the physician. 20 (12.2)
b) immediately contact the patient and repeat blood sampling, while also 
requesting more details about ‘fasting’.
8 (4.9)
c) verify the laboratory test results and refer the patient to a specialized facility 
for diabetes.
2 (1.2)
d) without verifying the laboratory test result, contact the patient and try to 
determine possible causes of hyperglycaemia.
3 (1.8)
e) verify the laboratory test result and include a comment to repeat blood 
glucose testing using a different sample and to check glucose in urine.
73 (44.5)





2. A laboratory test result is a critical value if it:
a) falls outside the reference interval. 1 (0.6)
b) is an abnormal result with medical significance. 7 (4.2)
c) indicates that a patient’s life is in danger and requires immediate notification 
of a physician or other clinical staff.
159 (95.2)
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3. Each laboratory should define its own critical values:
a) Yes. 78 (46.7)
b) No. 89 (53.3)





4. Critical values should be reported:
a) after confirmation by additional measurement of the same sample. 42 (25.1)
b) after confirmation by additional measurement of the same sample and after 
validation of the results.
89 (53.3)





5. Is a written recommended procedure about critical values available in your 
laboratory?
a) Yes. 144 (85.7)
b) No. 24 (14.3)








1. Elevated absolute eosinophil count with no clear cause on 5-part differential 
haematology analyser:
a) must be checked using Dunger’s method. 0 (0.0)
b) is sufficiently reliable without checking. 49 (30.6)
c) must be checked by microscopic examination of a peripheral blood smear. 111 (69.4)








2. Examination of urinary sediment reveals some bacteria (1+) and 0-5 leukocytes 
in the field of view (magnification, 400X). A urine test strip is positive for nitrite 
(1+) and leukocytes 500/μL (3+). In this situation you would:
a) correct the values of the urinary test strip according to microscopic 
examination of urinary sediment.
51 (32.1)
b) issue the laboratory test results without any correction or comment. 53 (33.3)
c) request a new urine sample without issuing the laboratory test results. 53 (33.3)
d) correct the values of the urinary sediment microscopic examination based on 
the urinary test strip results.
0 (0.0)
e) call technical support. 2 (1.3)
Comment: Non-compliant answer d) . 
PT – prothrombin time; INR – international normalized ratio; CCMB – Croatian Chamber of Medical Biochemists; TAT – turnaround 
time.
stantial variation in how they responded to certain 
questions about critical values; many lacked 
knowledge about age-dependent critical values 
and how to establish an intra-laboratory list of crit-
ical values. 
The questionnaire presented respondents with 
three scenarios involving interpretative comments 
in order to understand to what extent medical lab-
oratories in Croatia take an active role in interpret-
ing test results and communicating those inter-
pretations to clinicians orally or in writing. While 
laboratories varied in their responses to these sce-
narios, one third selected answers implying an ac-
tive role in interpretation of test results, either via a 
comment written on the report or contact with 
the clinician and/or patient. In various situations, 
up to a third of laboratories issued results without 
additional activities. 
Biochemia Medica 2017;27(1):144–52   http://doi.org/10.11613/BM.2017.018 
150
Lenicek Krleza J. et al. EQA of post-analytical phase in Croatia
The last group of questions asked laboratories 
how they proceed in the event of abnormal test 
results. For example, does the laboratory repeat 
the test and, if so, does it use the same or a new 
sample? Is the sample re-analysed using the same 
test procedure as before or a different procedure? 
After re-testing, are the initial and/or follow-up 
test results shown on the final report? Most labo-
ratories reported that they repeat testing to verify 
abnormal results. Nevertheless, one third reported 
that they issue results without such verification. 
Discussion
Harmonization and standardization of pre- and 
post-analytical phases of laboratory work are es-
sential for good clinical care. Since 2007, ISO stand-
ard 15189 has included assessment of pre- and 
post-analytical phases of testing as one of the re-
quirements for accreditation of medical laborato-
ries (6). Nevertheless, many providers of EQA 
schemes do not systematically assess the post-an-
alytical phase (2). Since 2014, all medical laborato-
ries in Croatia are required to participate in a na-
tional EQA scheme that includes post-analytical 
assessment. The present study aimed to assess the 
current state of laboratory compliance with the 
EQA scheme, as well as identify areas where clear-
er rules - or the first set of rules - need to be devel-
oped at the national level. This is an urgent prob-
lem, because only 11 of 198 (5.5%) registered med-
ical laboratories in Croatia are ISO 15189 - accredit-
ed, and most are planning to enter the accredita-
tion process soon (7). In the present study, we ret-
rospectively analysed the responses of medical 
laboratories to the Module 11 post-analysis ques-
tionnaire incorporated in the Croatian EQA exer-
cises since 2014. This questionnaire focused on the 
four main quality control indicators of the post-an-
alytical phase of testing. Our results indicate sub-
stantial heterogeneity in how medical laboratories 
in Croatia proceed in situations where no clear 
rules or guidelines exist. 
TAT is a frequently used quality indicator: it is easi-
ly tracked through the laboratory informatics sys-
tem, and ISO 15189 mandates that the TAT be es-
tablished for each type of test, through consulta-
tion between laboratory and clinician (item 5.8.11) 
(6). One challenge with standardizing TATs across 
laboratories is that the definition of TAT can vary 
depending on whether the laboratory is a primary, 
secondary or tertiary facility and whether the test 
is routine, emergency or specialized (8,9). Our re-
sults indicate that although most respondents 
know that TAT monitoring is an accreditation re-
quirement, they do not have a monitoring system 
in place. Nevertheless, most respondents do re-
cord when the laboratory sample is received and 
when validated test results are obtained or report-
ed. This likely reflects the widespread use of labo-
ratory informatics systems. 
ISO 15189 requires that laboratories apply stand-
ard procedures for recording and reporting critical 
values (items 5.8.1, 5.9.1 and 5.9.2) (6). Laboratories 
are also required to generate their own lists of crit-
ical values based on the local clinical situation, in 
consultation with clinicians (6,10,11). Most labora-
tories in our sample showed an understanding of 
critical values but not how to define own critical 
values list, or they neglected to adjust them based 
on patient age. In January 2015, CCMB published 
an updated and revised, ISO 15189 - compliant list 
of critical values (6,12), which includes critical val-
ues and reference intervals for neonatal patients 
(12,13). The recent release of this information at the 
national level may help to explain the heterogene-
ity in laboratory responses on our questionnaire. 
This information may help laboratories define their 
own lists of critical values and report critical values 
appropriately. Future work is needed to track labo-
ratory - level implementation of this knowledge 
around the country.
Most medical laboratories reported that they con-
firm critical values with additional measurement 
before reporting, which is consistent with CCMB 
recommendations. Approximately one fifth indi-
cated that they immediately report critical values 
without test repetition, which is consistent with 
practices at accredited laboratories in other coun-
tries (10,14,15) and reflects the fact that ISO 15189 - 
compliant laboratories may choose not to re-test 
in specific circumstances, such as when national 
guidelines in their country recommends it or when 
the use of advanced laboratory technology places 
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the initial result beyond reasonable doubt. Recent 
published results of survey on critical results re-
porting in Croatian medical laboratories found 
high score for re-analyse critical results before re-
porting (16). In general, Croatian laboratories are in 
compliance with valid CCMB recommendation.  
While those results based on a carefully designed 
scoring system are difficult to compare with our 
preliminary, descriptive results, the two studies 
may point to the need for more systematic re-
search in this area. 
Interpretative comments on the laboratory test re-
port can improve treatment outcomes (17). They 
are a widely used quality indicator and, since 2007, 
an obligatory part of ISO 15189 accreditation (6). 
Although the CCMB has stated since 2004 that ‘re-
marks related to the sample (lipemia, hyperbiliru-
binemia, haemolysis and others) are a mandatory 
part of every report of laboratory test results’, the 
type, format and position of the comments on the 
report are not clearly defined (13), nor do CCMB 
guidelines indicate which comments necessitate 
contacting the clinician. Our results indicate that, 
depending on the situation, 3-35% medical labo-
ratories do not flag abnormal results to the clini-
cian, either in writing or orally. In addition, one 
third of laboratories neither repeats the test nor 
performs additional actions in an effort to confirm 
the abnormal results. Abnormal results may be 
significant for diagnosis and treatment, and may 
call into question the reliability of the test results. 
Including interpretative comments on lab reports 
can help prevent the release of incorrect or less re-
liable test reports (18-20). Therefore, our results 
identify an urgent need to revise and update 
CCMB recommendations about interpretative 
comments on test reports, as well as a need for 
the CCMB and other groups to define when tests 
or sampling should be repeated or additional tests 
performed.    
A small proportion (12%) of respondent laborato-
ries left open-ended comments to one or more of 
the questions; nearly all these comments were 
that their laboratory did not routinely encounter, 
or had never encountered, the scenario described 
in the question. This suggests that many laborato-
ries feel they lack sufficient knowledge or experi-
ence to deal adequately with many post-analytical 
problems, despite the implementation of the Cro-
atian EQA scheme. This suggests the need for 
greater training opportunities for medical labora-
tories in the country.
The present study presents a preliminary picture 
of the early stages of post-analytical EQA at the 
national level in Croatia. It is based on a sampling 
of medical laboratories from around the country 
and makes use of a questionnaire tailored to the 
logistical, clinical, and regulatory situation in Croa-
tia. As with most questionnaire assessments, there 
is some risk that practices reported on the survey 
do not reflect actual practices in the respondent 
laboratory. To reduce this risk, we asked that the 
questionnaires be filled out by professional labo-
ratory staff responsible for quality control. Anoth-
er limitation of our study is that the response rate 
ranged from 81% to 90%, raising the possibility 
that our sample was biased. For example, perhaps 
laboratories that felt more confident about their 
knowledge and practices were more likely to re-
spond to our survey. If this is true, then our study 
may underestimate the lack of alignment with 
post-analytical best practices, which only reinforc-
es our conclusion that much more needs to be 
done to accelerate the harmonization of post-ana-
lytical procedures in Croatia. A third limitation is 
that the survey was not extensive enough to offer 
comprehensive insights into laboratory practices 
and attitudes. While this may have helped ensure 
a high response rate for the preliminary analysis 
here, future work may wish to look at these issues 
in greater detail. 
In conclusion, assessment of post-analytical quali-
ty indicators such as TAT, critical values and inter-
pretative comments are well recognized by both 
CCMB and ISO 15189, although clear definition of 
these terms, guidelines compliance and actions to 
be taken by laboratories are often incomprehensi-
ble. The results of Module 11 survey in Croatia 
highlights major obstacles to harmonization and 
standardization of post-analytical practices at na-
tional level. Future EQA exercises should reinforce 
the importance of filling out this survey. 
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